Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?

Cancer Biology and Therapy

Volumn 17, Issue 5, 2016, Pages 467-469

  Leibrand, Crystal R ^a   Price, Douglas K ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Androgen receptor; prostate cancer; splice variants

Indexed keywords

ABIRATERONE; ANDROGEN; ANDROGEN RECEPTOR; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; AR PROTEIN, HUMAN; BIOLOGICAL MARKER; ISOPROTEIN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; DRUG EFFICACY; HUMAN; LIGAND BINDING; MALE; GENETICS;

BIOMARKERS; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN;

EID: 84963603681     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1156274     Document Type: Article

References (19)

1. E.S.Antonarakis, C.Lu, C.Wang, B.Luber, M.Nakazawa, J.C.Roeser, Y.Chen, T.A.Mohammad, Y.Chen, H.L.Fedor, T.L.Lotan, Q.Zheng, A.M.De Marzo, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. NEJM 2014; 371(11):1028-1038; PMID:25184630; http://dx.doi.org/10.1056/NEJMoa1315815
2. E.S.Antonarakis, C.Lu, B.Luber, H.Wang, Y.Chen, M.Nakazawa, R.Nadal, C.J.Paller, S.R.Denmeade, M.A.Carducci, M.A.Eisenberger, J.Luo. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncology 2015; 1(5):582-591; PMID:26181238; http://dx.doi.org/10.1001/jamaoncol.2015.1341
3. M.L.Zhu, C.M.Horbinski, M.Garzotto, D.Z.Qian, T.M.Beer, N.Kyprianou. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Research 2010; 70(20):7992-8002; PMID:20807808; http:/dx.doi.org/10.1158/0008-5472.CAN-10-0585
4. M.Thadani-Mulero, L.Portella, S.Sun, M.Sung, A.Matov, R.L.Vessella, E.Corey, D.M.Nanus, S.R.Plymate and P.Giannakakou. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 2014; 74: 2270-2282; PMID:24556717; http://dx.doi.org/10.1158/0008-5472.CAN-13-2876
5. G.Zhang, X.Liu, J.Li, E.Ledet, X.Alvarez, Y.Qi, X.Fu, O.Sartor, Y.Dong, H.Zhang. Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. Oncotarget 2015; 6(27):23358-71; PMID:26160840 [Epub ahead of print]
6. I.Pastina, E.Giovannetti, A.Chioni, T.M.Sissung, F.Crea, C.Orlandini, D.K.Price, C.Cianci, W.D.Figg, S.Ricci, R.Danesi. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer 2010; 10:511; PMID:20875115; http://dx.doi.org/doi:10.1186/1471-2407-10-511
7. T.M.Sissung, R.Danesi, D.K.Price, S.M.Steinberg, R.de Wit, M.Zahid, N.Gaikwad, E.Cavalieri, W.L.Dahut, D.L.Sackett, W.D.Figg, A.Sparreboom. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Molecular Cancer Therapeutics 2008; 7(1):19-26; PMID:18187806; http://dx.doi.org/10.1158/1535-7163.MCT-07-0557
8. H.Pressler, T.M.Sissung, D.Venzon, D.K.Price, W.D.Figg. Expression of OATP Family Members in Hormone-Related Cancers: Potential Markers of Progression. PLoS One 2011; 6(5):e.20372; PMID:21625523; http://dx.doi.org/10.1371/journal.pone.0020372
9. M.Nakazawa, C.Lu, Y.Chen, C.J.Paller, M.A.Carducci, M.A.Eisenberger, J.Luo, E.S.Antonarakis. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Annals of Oncology 2015; 26:1859-1865; PMID:26117829; http://dx.doi.org/10.1093/annonc/mdv282
10. B.Cao, Y.Qi, G.Zhang, D.Xu, Y.Zhan, X.Alvarez, Z.Guo, X.Fu, S.R.Plymate, O.Sartor, H.Zhang, Y.Dong. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 2014; 5(6):1646-56; PMID:24722067
11. Z.Yu, S.Chen, A.G.Sowalsky, O.S.Voznesensky, E.A.Mostaghel, P.S.Nelson, C.Cai, S.P.Balk. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clinical Cancer Research 2015; 20(6):1590-1600; PMID:24449822; http://dx.doi.org/10.1158/1078-0432.CCR-13-1863
12. D.Kong, S.Sethi, Y.Li, W.Chen, W.A.Sakr, E.Heath, F.H.Sarkar. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. Prostate 2015; 75(2):161-174; PMID:25307492; http://dx.doi.org/10.1002/pros.22901
13. C.Liu, W.Lou, Y.Zhu, N.Nadiminty, C.T.Schwartz, C.P.Evans and A.C.Gao. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration resistant prostate cancer. Clin Cancer Res 2014; 20:3198-3210; PMID:24740322; http://dx.doi.org/10.1158/1078-0432.CCR-13-3296
14. C.Liu, W.Lou, C.Armstrong, Y.Zhu, C.P.Evans and A.C.Gao. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate 2015; 75(13):1341-53; PMID:25970160; http://dx.doi.org/10.1002/pros.23015
15. F.Zengerling, A.Azoitei, A.Herweg, F.Jentzmik, M.V.Cronauer. Inhibition of IGF1R diminishes transcriptional activity of the androgen receptor and its constitutively active, Cterminally truncated counterparts Q640X and ARV7. World J Urol 2015; PMID:26318637; http://dx.doi.org/10.1007/s00345-015-1674-5 [Epub ahead of print]
16. N.Nadiminity, R.Tummala, C.Liu, W.Lou, C.P.Evans, A.C.Gao. NF-kB2/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer. Molecular Cancer Therapeutics 2015; 14(8):1884-1895; PMID:26056150; http://dx.doi.org/10.1158/1535-7163.MCT-14-1057
17. J.Stockley, E.Markert, Y.Zhou, C.N.Robson, D.J.Elliott, J.Lindberg, H.Y.Leung, P.Rajan. The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7. Nature Scientific Reports 2015; 5:13426; PMID:26310125; http://dx.doi.org/10.1038/srep13426
18. D.Xu, Y.Zhan, Y.Qi, B.Cao, S.Bai, W.Xu, S.S.Gambhir, P.Lee, O.Sartor, E.K.Flemington, H.Zhang, C.Hu, Y.Dong. Androgen receptor splice variants dimerize to transactivate target genes. Cancer Research 2015; 75(17):3663-71; PMID:26060018; http://dx.doi.org/10.1158/0008-5472.CAN-15-0381
19. A.K.Kwegyir-Afful, S.Ramalingam, P.Purushottamachar, V.P.Ramamurthy, V.Njar. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistance prostate cancer xenografts in vivo. Oncotarget 2015; 6(29):27440-60; PMID:26196320 [Epub ahead of print]